Harness Therapeutics nominated HRN001, a first-in-class drug candidate for Huntington's Disease, and established a clinical advisory board.
Harness Therapeutics is transforming the treatment of neurodegenerative diseases by unlocking a new class of genetically validated disease-modifying targets through precision protein upregulation
Harness Therapeutics is transforming the treatment of neurodegenerative diseases by unlocking a new class of genetically validated disease-modifying targets through precision protein upregulation. Their proprietary MISBA® platform enables finely tuned, controlled increases in protein expression, allowing for therapeutic targeting of complex biological pathways that have remained inaccessible with traditional approaches.